Director Ramiro Peru sold 753 shares of Elevance Health Inc (ELV, Financial) on August 5, 2024, as reported in a recent SEC Filing. Following this transaction, the insider now owns 8,744 shares of the company. The shares were sold at a price of $531.52, valuing the transaction at approximately $400,005.36.
Elevance Health Inc (ELV, Financial), formerly known as Anthem Inc, operates as a health benefits company in the United States. It provides a range of medical and specialty products, primarily through health plans, government sponsored managed care plans, and Medicare and Medicaid programs.
Over the past year, Ramiro Peru has sold a total of 1,506 shares of the company and has not made any purchases. The insider transaction history for Elevance Health Inc shows a pattern of 10 insider sells and no insider buys over the same timeframe, indicating a trend of insider selling.
On the valuation front, Elevance Health Inc's shares are currently trading at a price-earnings ratio of 18.36. The company's market cap is $121.43 billion. According to the GF Value, the intrinsic value estimate for the stock is $543.89, suggesting that the stock is Fairly Valued with a price-to-GF-Value ratio of 0.98.
The GF Value is calculated based on historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted for the company's past performance and estimated future performance.
This recent insider sell by Director Ramiro Peru could be a point of interest for investors and market watchers, providing insight into insider sentiment at Elevance Health Inc.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
